213 related articles for article (PubMed ID: 32632558)
1. Anti-coagulation for COVID-19 treatment: both anti-thrombotic and anti-inflammatory?
Paar V; Wernly B; Zhou Z; Motloch LJ; Hoppe UC; Egle A; Lichtenauer M
J Thromb Thrombolysis; 2021 Jan; 51(1):226-231. PubMed ID: 32632558
[TBL] [Abstract][Full Text] [Related]
2. Induction of Exaggerated Cytokine Production in Human Peripheral Blood Mononuclear Cells by a Recombinant SARS-CoV-2 Spike Glycoprotein S1 and Its Inhibition by Dexamethasone.
Olajide OA; Iwuanyanwu VU; Lepiarz-Raba I; Al-Hindawi AA
Inflammation; 2021 Oct; 44(5):1865-1877. PubMed ID: 33860869
[TBL] [Abstract][Full Text] [Related]
3. Rapid evolution of our understanding of the pathogenesis of COVID-19: Implications for therapy.
Mustafa F; Giles R; Pepper MS
S Afr Med J; 2020 Oct; 110(12):1180-1185. PubMed ID: 33403962
[TBL] [Abstract][Full Text] [Related]
4. COVID-19-associated coagulopathy and disseminated intravascular coagulation.
Asakura H; Ogawa H
Int J Hematol; 2021 Jan; 113(1):45-57. PubMed ID: 33161508
[TBL] [Abstract][Full Text] [Related]
5. Effects of β-Blockers on the Sympathetic and Cytokines Storms in Covid-19.
Al-Kuraishy HM; Al-Gareeb AI; Mostafa-Hedeab G; Kasozi KI; Zirintunda G; Aslam A; Allahyani M; Welburn SC; Batiha GE
Front Immunol; 2021; 12():749291. PubMed ID: 34867978
[TBL] [Abstract][Full Text] [Related]
6. Influence of dabigatran on pro-inflammatory cytokines, growth factors and chemokines - Slowing the vicious circle of coagulation and inflammation.
Paar V; Jirak P; Gruber S; Prodinger C; Cadamuro J; Wernly B; Motloch LJ; Haschke-Becher E; Hoppe UC; Lichtenauer M
Life Sci; 2020 Dec; 262():118474. PubMed ID: 32961229
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 infection and thrombotic complications: a narrative review.
Moschonas IC; Tselepis AD
J Thromb Thrombolysis; 2021 Jul; 52(1):111-123. PubMed ID: 33449290
[TBL] [Abstract][Full Text] [Related]
8. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy.
Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Ronconi G
J Biol Regul Homeost Agents; 2020; 34(6):1971-1975. PubMed ID: 33016027
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological mechanism of immunomodulatory agents for the treatment of severe cases of COVID-19 infection.
Bahari Z; Jangravi Z; Ghoshooni H; Afarinesh MR; Meftahi GH
Inflamm Res; 2021 Apr; 70(4):389-405. PubMed ID: 33608746
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic options for the management of severe COVID-19: A rheumatology perspective.
Mendoza-Pinto C; García-Carrasco M; Munguía Realpozo P; Méndez-Martínez S
Reumatol Clin (Engl Ed); 2021 Oct; 17(8):431-436. PubMed ID: 34625144
[TBL] [Abstract][Full Text] [Related]
11. Specific cytokines in the inflammatory cytokine storm of patients with COVID-19-associated acute respiratory distress syndrome and extrapulmonary multiple-organ dysfunction.
Wang J; Yang X; Li Y; Huang JA; Jiang J; Su N
Virol J; 2021 Jun; 18(1):117. PubMed ID: 34088317
[TBL] [Abstract][Full Text] [Related]
12. Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy.
Iovino L; Thur LA; Gnjatic S; Chapuis A; Milano F; Hill JA
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986127
[TBL] [Abstract][Full Text] [Related]
13. The Cross-Talk between Thrombosis and Inflammatory Storm in Acute and Long-COVID-19: Therapeutic Targets and Clinical Cases.
Acanfora D; Acanfora C; Ciccone MM; Scicchitano P; Bortone AS; Uguccioni M; Casucci G
Viruses; 2021 Sep; 13(10):. PubMed ID: 34696334
[TBL] [Abstract][Full Text] [Related]
14. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?
Panigrahy D; Gilligan MM; Huang S; Gartung A; Cortés-Puch I; Sime PJ; Phipps RP; Serhan CN; Hammock BD
Cancer Metastasis Rev; 2020 Jun; 39(2):337-340. PubMed ID: 32385712
[TBL] [Abstract][Full Text] [Related]
15. Immune Profiling of COVID-19 in Correlation with SARS and MERS.
Khalil BA; Shakartalla SB; Goel S; Madkhana B; Halwani R; Maghazachi AA; AlSafar H; Al-Omari B; Al Bataineh MT
Viruses; 2022 Jan; 14(1):. PubMed ID: 35062368
[TBL] [Abstract][Full Text] [Related]
16. Phenylmethimazole is a candidate drug for the treatment of severe forms of coronavirus disease 2019 (COVID-19) as well as other virus-induced "cytokines storm".
Giuliani C; Bucci I; Napolitano G
Med Hypotheses; 2021 Jan; 146():110473. PubMed ID: 33385879
[TBL] [Abstract][Full Text] [Related]
17. Complement activation and coagulopathy - an ominous duo in COVID19.
Tomo S; Kumar KP; Roy D; Sankanagoudar S; Purohit P; Yadav D; Banerjee M; Sharma P; Misra S
Expert Rev Hematol; 2021 Feb; 14(2):155-173. PubMed ID: 33480807
[TBL] [Abstract][Full Text] [Related]
18. Elevated cytokines and chemokines in peripheral blood of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma.
Fanning SL; Korngold R; Yang Z; Goldgirsh K; Park S; Zenreich J; Baker M; McKiernan P; Tan M; Zhang B; Donato ML; Perlin DS
PLoS Pathog; 2021 Oct; 17(10):e1010025. PubMed ID: 34714894
[TBL] [Abstract][Full Text] [Related]
19. Understanding the andromeda strain - The role of cytokine release, coagulopathy and antithrombin III in SARS-CoV2 critical illness.
Mir N; D'Amico A; Dasher J; Tolwani A; Valentine V
Blood Rev; 2021 Jan; 45():100731. PubMed ID: 32829961
[TBL] [Abstract][Full Text] [Related]
20. Platelets and COVID-19.
Rohlfing AK; Rath D; Geisler T; Gawaz M
Hamostaseologie; 2021 Oct; 41(5):379-385. PubMed ID: 34695854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
